Permapen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Permapen

Property Description
Active ingredient Benzathine Benzylpenicillin
Form Injectable Suspension
Pharmacological class Penicillin Antibiotic (Beta-lactam antimicrobial)
Type Long-acting, Repository compound
Origin Semisynthetic salt derivative of Natural Penicillin

Permapen: Definition, Active Ingredient, and Pharmacological Class

Permapen is a registered trade name for a sterile, single-ingredient antibacterial agent whose active component is Benzathine Benzylpenicillin (Penicillin G Benzathine). This drug is classified within the Penicillin antibiotic class, which is a subgroup of the Beta-lactam antimicrobials. This classification reflects its mechanism of interference with bacterial cell wall integrity. The active substance is a specialized semisynthetic salt derivative of Benzylpenicillin (Penicillin G), a natural fermentation product, synthesized specifically to enhance the duration of its effect. The compound exerts bactericidal activity, which directly targets Penicillin Binding Proteins (PBPs) in susceptible organisms.

The Purpose and Unique Long-Acting Form of Permapen

The formulation of Permapen as an Injectable Suspension is a critical distinguishing factor, intended for deep Intramuscular administration only. This form, often supplied pre-filled, consists of the low-solubility active ingredient dispersed within a high-viscosity aqueous vehicle, which creates a characteristic repository effect. This formulation maintains effective drug concentrations over extended periods, a feature that differentiates it from short-acting crystalline penicillins. The overall purpose of Permapen is to leverage this prolonged presence, offering sustained bactericidal activity essential for continuous antimicrobial protection, used for the clearance of specific bacterial infections or for long-term prophylaxis in high-risk patient groups.

Regulatory References

  1. WHO Essential Medicines List - Benzathine Benzylpenicillin

What side effects are possible with Permapen?

Possible Side Effects and Safety Information

The officially documented adverse effects for Benzathine Benzylpenicillin (Permapen) are classified by regulatory agencies based on the system or organ affected and the frequency of occurrence. The safety profile is heavily defined by the potential for Hypersensitivity Reactions and events related to its injectable suspension form.


Official Frequency Classification of Adverse Reactions

The following is a summary of adverse effects classified by incidence, reflecting official regulatory standards:

  • Common: Reactions at the injection site, specifically pain and induration (hardening).
  • Uncommon: Skin reactions, including rash and pruritus (itching).
  • Rare: More distinct allergic reactions, such as urticaria (hives) and angioedema (swelling beneath the skin).
  • Very Rare: Severe systemic events, including anaphylactic shock and pseudomembranous colitis.
  • Not Known: Serious cutaneous adverse reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as blood disorders like hemolytic anemia.

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the risk of Anaphylactic Shock, a potentially fatal systemic allergic reaction. Other serious adverse reactions include the severe cutaneous reactions (SJS/TEN) and potentially life-threatening forms of antibiotic-associated diarrhea.

Population-specific safety considerations note that individuals with Impaired Renal Function may experience reduced drug elimination, which could increase the risk of adverse effects. Furthermore, the label states the medicine is contraindicated in patients with a known history of hypersensitivity to any penicillin.

Treatment of certain infections may be associated with the Jarisch-Herxheimer Reaction, a transient systemic event that typically occurs within the first 24 hours after administration.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Benzathine Benzylpenicillin (Permapen) based on severe systemic effects and mandatory emergency actions.

Documented Overdose Manifestations

Overdose is formally documented as potentially presenting with acute manifestations primarily related to the Central Nervous System (CNS). Documented signs include hyperreflexia, myoclonic jerks, and severe neurological events such as convulsions and epileptic seizures. Gastrointestinal effects, including nausea, vomiting, and diarrhea, have also been reported. The potential for neurotoxicity is officially noted to be increased in patients with impaired renal function due to reduced drug clearance.

Life-Threatening Outcomes and Emergency Actions

Severe overdose can lead to life-threatening outcomes, including status epilepticus. Regulatory labeling emphasizes that the inadvertent intravenous administration of the repository suspension carries an extreme risk of cardiopulmonary arrest and death. The official guidance mandates that patients must seek immediate medical attention or contact emergency services upon suspicion of an overdose.

Management and Antidote Status

Management of overdosage is symptomatic and supportive, as no specific antidote is known. Officially described supportive measures include the use of anticonvulsant therapy to control seizures and the procedural use of haemodialysis to assist in removing the active component from the circulation.

Therapeutic Uses of Permapen

Permapen (Benzathine Benzylpenicillin) is commonly used in clinical practice across key therapeutic domains. It is considered relevant due to its long-acting properties, which help manage specific infections and is applied to assist with continuous supportive relief. Core therapeutic uses include both active treatment and long-term prophylaxis against recurrent disease.

The primary therapeutic applications include the management of acute Streptococcal pharyngitis and tonsillitis, treatment for various stages of Syphilis, and managing other systemic Treponema infections like Yaws and Pinta. Its sustained antimicrobial coverage is considered relevant for high-risk patient groups, especially those requiring secondary prophylaxis against the recurrence of Acute Rheumatic Fever and the resulting damage to the heart. This long-term use is relevant in clinical settings.

The extended duration of action supports the patient by supporting sustained management of the infectious risk, especially in preventive care.

This process plays a role in managing the pathogen, which contributes to improved day-to-day comfort by helping to ease pronounced symptoms like fever and severe localized throat discomfort. Furthermore, this support may assist in managing the risk of recurrent systemic inflammatory damage and maintaining functional stability over time.


Quick Fact: Support for Systemic and Localized Discomfort

The medication is commonly used to help manage symptom clusters associated with acute bacterial infections, as well as the systemic manifestations linked to Treponemal diseases, contributing to easing the overall symptom load during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Permapen?

Permapen (Benzathine Benzylpenicillin) eligibility is strictly defined by regulatory documents, focusing primarily on hypersensitivity status and the route of administration.


Populations For Whom Use is Contraindicated

The medicine is absolutely contraindicated for specific populations and methods of use:

  • Patients with a documented history of hypersensitivity to any penicillin or those with a known allergy to cephalosporin antibiotics (due to potential cross-sensitivity).
  • Intravenous (IV) or Intra-arterial (IA) administration is prohibited due to the risk of severe neurovascular damage; the drug must only be administered by deep intramuscular injection.
  • It is not recommended for patients with Neurosyphilis, as the formulation does not achieve adequate concentrations in the cerebrospinal fluid.

Age-Group and Condition-Specific Eligibility

  • Age Eligibility: Use is established in adults, adolescents, children, and neonates. Efficacy and safety have been confirmed across all pediatric groups.
  • Renal Function: Patients with impaired renal function require caution, as excretion is delayed, which may necessitate adjustments for repeated dosing.
  • Pregnancy and Lactation: Use during pregnancy is generally permitted when indicated. Use during lactation is permitted with caution, as penicillin is excreted in small amounts into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Permapen (Benzathine Benzylpenicillin) identifies specific interaction patterns that may alter drug exposure or pharmacodynamic effect. These statements reflect constraints defined in official government prescribing information.


Documented Interaction Patterns

Interacting Substance Official Interaction Type and Outcome
Probenecid Pharmacokinetic: Inhibits renal tubular secretion of Permapen, leading to an officially documented increase in serum concentration and prolongation of elimination half-life of the penicillin.
Methotrexate Exposure Modification: Permapen is reported to reduce the excretion of methotrexate, which may result in increased toxicity of methotrexate. Co-administration is not recommended.
Bacteriostatic Antibiotics Pharmacodynamic: Co-administration with agents like tetracycline is not recommended due to the potential for antagonistic action that could diminish the bactericidal effect of Permapen.
Oral Anticoagulants Hemostatic Risk: May increase the anti-vitamin K effect and the associated risk of bleeding. Increased monitoring is required.

Population-Specific Interaction Notes

Caution is required in patients with renal impairment, as the drug is primarily renally eliminated. Slower clearance may increase the risk of drug accumulation. Furthermore, the risk of bleeding when co-administered with Oral Anticoagulants is specifically noted as being higher in elderly or patients with kidney or liver impairment.

Mechanism of Action

Mechanism of Action: Cell Wall Inhibition and Sustained Release

Permapen (Penicillin G) acts as an irreversible covalent inhibitor of bacterial enzymes known as Penicillin-Binding Proteins (PBPs). Specifically, the drug's beta-lactam ring binds to and inactivates bacterial transpeptidases, thereby blocking the crucial final step of peptidoglycan cross-linking necessary for cell wall assembly. This inhibition leads to the structural failure of the bacterial cell wall and triggers osmotic rupture (lysis) and death in susceptible, actively dividing bacteria, representing the core bactericidal consequence. The drug is formulated as the benzathine salt, an insoluble compound that creates a local tissue depot upon injection. This depot mechanism ensures the continuous, slow hydrolysis and release of active Penicillin G into the circulation, maintaining the inhibition of cell wall synthesis over an extended duration. Mechanistic efficacy is constrained by enzymatic resistance, such as the expression of beta-lactamase, which inactivates the drug before target binding occurs.

Dosage and Administration Information

Administration of Permapen (Benzathine Benzylpenicillin) follows the requirements of its specialized, long-acting Injectable Suspension form. The approved route of administration is exclusively deep Intramuscular (IM) injection, and the medication is expressly forbidden from all other routes, including intravenous or intra-arterial delivery.

Dosing Regimens and Frequency

Context of Use Standard Adult Dose Frequency and Schedule
Acute Streptococcal Infection 1,200,000 units Single administration
Late Latent Syphilis 2,400,000 units Once weekly for three consecutive weeks
Secondary Prophylaxis Varies by patient risk Every 3 to 4 weeks for extended duration

Procedural and Population Constraints

The viscous nature of the suspension mandates specific procedural conditions for administration. The injection must be given slowly and steadily, typically over 2 to 3 minutes, and the syringe may be warmed to room temperature beforehand to facilitate proper flow. For large-volume doses, such as 2,400,000 units, the suspension may be divided into two separate injections and administered into two different sites. Administration sites should be rotated for repeated use in long-term regimens. A reduction in dose is required for patients with severely impaired renal function to prevent drug accumulation, a modification managed through calculated dosing based on creatinine clearance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Permapen

Evidence for Use in Treating Early Syphilis

Research into the use of this medicine for syphilis has primarily involved comparative studies. These trials were designed to explore the single-dose injectable treatment approach in studies that involved other therapeutic methods. The main outcomes research examined were changes in blood tests, specifically monitoring for a ge 4-fold decrease in the nontreponemal antibody titers (like RPR/VDRL) at specific time points. These studies included adults with untreated syphilis, and a portion of the research specifically monitored findings in individuals who were also co-infected with HIV.

Official regulatory reviews describe the outcomes monitored in the studies as the basis for evaluation. However, research is limited in providing insight into the use of this formulation for later stages of syphilis, such as late latent or tertiary disease. There is also limited information on long-term outcomes, particularly regarding severe neurological or cardiovascular complications.

Evidence for Use in Preventing Recurrent Rheumatic Fever

This evidence base for secondary prophylaxis in conditions characterized by recurrent Acute Rheumatic Fever (ARF) and Rheumatic Heart Disease (RHD) was developed using systematic reviews, meta-analyses, and decades of long-term observational data. The studies observed patients over extended intervals, often years, to monitor the incidence of ARF recurrence during regular administration of the long-acting injection. Researchers also monitored outcomes related to the incidence of new Group A Streptococcal (GAS) throat infections.

The evidence has been used by major global health organizations to inform their guidelines. What remains uncertain is the effect of the ongoing treatment on the actual progression or regression of established RHD. Evidence concerning long-term outcomes, such as mortality, is noted as having very low certainty, and research is ongoing to provide better insight into the optimal duration of administration required for different patient groups.

Acknowledged Research Gaps and Uncertainties

A primary limitation is that comparative evidence is lacking for some of the late-stage manifestations of treponemal diseases. For prophylaxis, the evidence base is relied upon by major health organizations, but the long-term effects on the overall progression of RHD are not fully established. Furthermore, research does not determine whether an individual will respond similarly to the group patterns described in the studies. The study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. RCT Results: Is a Single Dose of Benzathine Penicillin G Actually Sufficient to Treat Early Syphilis in Patients with HIV? (Hook et al. study summary)
  2. Secondary prophylaxis with penicillin for rheumatic fever or established rheumatic heart disease - a rapid review (Focus on mortality/RHD progression certainty)
  3. WHO Guidelines for the treatment of Treponema pallidum (syphilis) (Section on early and late syphilis treatment and pregnancy)
  4. Therapeutics for rheumatic fever and heart disease (Australian Prescriber - provides guidelines context and RHD progression uncertainty)
  5. Benzathine Penicillin (StatPearls - NCBI Bookshelf, used for general indication and patient group context)

Frequently Asked Questions (FAQ)

Common questions about Permapen (FAQ)

Q: How quickly does Permapen start working after the injection?

The official product information indicates that Permapen, which is a long-acting formulation, releases the active substance (Penicillin G) slowly from the injection site (known as the depot). The onset of its therapeutic effect is therefore tied to this initial, sustained release of the active drug into the bloodstream.


Q: How long does the effect of one Permapen shot last?

The unique long-acting formulation of Permapen is designed to maintain effective antibacterial concentrations in the body over an extended period. Depending on the prescribed dose, this sustained effect may last anywhere from one to four weeks after a single injection. This duration is what makes it suitable for long-term treatments and prophylaxis.


Q: What are the most common side effects people report with Permapen?

According to official regulatory documents, the most common adverse effects reported are local reactions at the injection site. These typically include pain and induration, which is the term for a local hardening or stiffness of the tissue where the shot was given.


Q: Does Permapen cause pain at the injection site?

Yes, regulatory labeling confirms that pain at the injection site is listed as a common adverse reaction for this medication. This is often associated with the dense nature of the suspension and the required deep intramuscular administration.


Q: Do people sometimes have allergic reactions to Permapen?

Yes, official warnings highlight that allergic reactions are a known risk with this medication. Reactions can range from common skin reactions like a rash or itching to rare but serious reactions such as anaphylactic shock (a severe, whole-body allergic reaction) or hives.


Q: Does Permapen interact with blood thinners?

Official drug interaction data states that Permapen may interact with certain oral anticoagulants (blood thinners). This can potentially increase the anti-vitamin K effect, which is associated with an increased risk of bleeding. Regulatory documents state that if these medications are co-administered, increased monitoring by a healthcare professional is noted as necessary.


Q: Do certain medical conditions make Permapen less effective?

Regulatory information indicates that the drug's effectiveness may be compromised if the infection is caused by bacteria that produce an inactivating enzyme called beta-lactamase. Additionally, this specific formulation is not recommended for conditions like neurosyphilis because it is known to achieve inadequate drug concentrations in the cerebrospinal fluid.


Q: Why do doctors prefer a long-acting penicillin like Permapen in certain situations?

The unique long-acting formula establishes a drug depot that ensures the continuous, sustained release of the antibiotic over weeks. This prolonged action is often preferred to ensure continuous antimicrobial protection, which is critical for long-term protection regimens like rheumatic fever prophylaxis or to help ensure patient compliance in the treatment of diseases like syphilis.


Q: Is Permapen the same as Bicillin L-A?

Permapen and Bicillin L-A are both trade names used for the same active ingredient, which is Benzathine Benzylpenicillin. Both are long-acting injectable forms of penicillin and share the same core pharmacological mechanism.


Q: Is it safe to drink alcohol while the Permapen is still in your system?

While specific governmental regulatory labeling may not list a direct contraindication, general drug safety information suggests that patients be aware of any potential interactions. It is recommended to discuss the use of alcohol with a healthcare professional to ensure that potential side effects are considered while the medication is active in the body.


Q: What should I do if I feel dizzy after receiving a Permapen injection?

Dizziness is a possible reported side effect. If dizziness is severe or accompanied by other serious symptoms like difficulty breathing or a change in heartbeat, official safety information advises seeking medical assistance immediately. Patients are advised to consult with a healthcare professional regarding any concerning symptoms.


Q: Can children receive Permapen?

Yes, official drug labeling confirms that the use of Permapen is established across all pediatric groups. It is approved for administration by deep intramuscular injection in neonates, children, and adolescents, with the dose determined by a healthcare professional based on the specific infection.


Q: Why is Permapen used for prevention (prophylaxis) in some cases?

Permapen is officially indicated for the secondary prophylaxis of rheumatic fever. Its prolonged action ensures that effective antibiotic concentrations are continuously maintained in the body, which is critical for preventing the recurrence of streptococcal infections linked to the disease.


Q: How long does Permapen stay in your body?

Due to its design as a slow-release depot, the drug remains in the body for an extended time. Pharmacokinetic studies show that the active drug, Penicillin G, has been detected in urine for up to 12 weeks following a single intramuscular injection.


Q: Is it normal to feel tired for a day or two after getting a Permapen shot?

Regulatory drug surveillance has included reports of tiredness (fatigue) and lack of energy (asthenia) among the possible systemic adverse effects. If experienced, these symptoms are typically transient and may resolve within a few days of the injection.


Q: What's the research evidence regarding Permapen's long-term effectiveness?

The evidence base, especially for the prevention of rheumatic fever, is robust, supported by systematic reviews and decades of observational data. However, regulatory research reviews note that there remains uncertainty regarding its long-term effect on the actual progression or reversal of established rheumatic heart damage.


Q: Are there any studies comparing Permapen to oral antibiotics for the same condition?

Yes, official guidelines and clinical review sections often reference comparative studies. These trials were designed to explore the single-dose injectable treatment approach versus various oral antibiotic regimens for specific conditions such as strep throat or early syphilis.


Q: Can a Permapen shot be split into two smaller injections?

Official administration guidance confirms that for high-volume doses, such as those used in syphilis treatment, the suspension may need to be divided into two separate injections. These must be administered by a healthcare professional into two different deep intramuscular sites.


Q: What happens if you miss the scheduled time for a Permapen dose?

Current governmental treatment guidelines for multi-dose regimens indicate that if a dose is missed or delayed, a healthcare professional may recommend a re-evaluation and potentially restarting the entire course of therapy. Patients are advised to consult their healthcare provider immediately if a scheduled dose is missed.


Q: Can taking Permapen cause a yeast infection?

Official labeling for Permapen includes a warning that prolonged or repeated use may lead to a superinfection. This means the antibiotic can disrupt the normal balance of microorganisms, which may result in the overgrowth of non-susceptible organisms, including the development of a fungal infection (yeast infection).


Q: What's the shelf life of Permapen if it hasn't been used?

Regulatory information establishes a specific expiration date (shelf life) for the product. To remain stable and effective until that date, the medication must be stored correctly, primarily under controlled refrigerated temperatures between 2 and 8 C.


Q: Do people with pre-existing heart conditions need to be careful with Permapen?

Official warnings note that extreme caution is required, particularly due to the risk of severe adverse events if the medication were to be inadvertently injected into a blood vessel. Patients with any pre-existing conditions are advised to ensure their healthcare provider is fully aware of their medical history.


Q: Does Permapen help with the fever associated with a bacterial infection?

Successful antibiotic treatment is generally expected to lead to the resolution of fever as the underlying bacterial cause is eliminated. However, it is also important to note that fever can be a temporary side effect of the Jarisch-Herxheimer reaction that can occur following treatment for specific infections.


Q: Why does the injection site sometimes become red or swollen after the shot?

Redness (erythema) and swelling are common local reactions to the injection, which are officially listed as potential adverse events. This often relates to the localized presence of the dense, slowly-releasing drug suspension and the physical trauma of the required deep intramuscular administration.


Q: Is Permapen still a commonly used antibiotic today?

Yes, Permapen remains a commonly used and important antibiotic. It is featured on the World Health Organization's Model List of Essential Medicines and is the primary recommended treatment in major governmental health guidelines for specific conditions such as syphilis and rheumatic fever prophylaxis.


Q: Why is it important to complete the full treatment regimen with Permapen?

It is essential to follow the full treatment regimen to ensure the complete elimination of the targeted bacteria. This adherence is a fundamental principle of antibiotic use designed to prevent the development of drug-resistant bacteria and minimize the risk of the infection recurring.

How should Permapen be stored and disposed of?

How to Store and Dispose of Permapen (Penicillin G Benzathine)

Permapen injectable suspension requires mandatory temperature control to maintain the stability of the long-acting formulation.


Official Storage Requirements

  • Refrigerated Storage: The medicine must be stored in a refrigerator at a temperature between 2 and 8 C (36 to 46 F).
  • Freezing is Prohibited: The product must be kept from freezing, as freezing compromises the suspension and renders the medication unusable.
  • Child Safety: All medicine must be kept out of the sight and reach of children.
  • Temporary Storage: The product cannot be returned to refrigerated storage once removed for a permitted single, time-limited excursion.

Disposal of Unused Medicine

Expired or unused Permapen should be disposed of through an authorized drug take-back program. The used syringe and any leftover contents require specialized disposal according to sharps handling instructions. The medicine should not be flushed down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Permapen found in:

A-Z Index: